In 2006, Japanese researchers [7] conducted a phase II clinical trial, using gefitinib as a first-line treatment for 16 patients with advanced NSCLC with EGFR mutations, achieving a response rate of 75%. Here, EGFR is linked to non-small cell lung carcinoma.